SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based healthcare technology company that provides a cloud-native data analytics platform for interpreting complex medical and genomic datasets. Its core offering, SOPHiA DDM, is used by hospitals, cancer centers, laboratories, and life sciences organizations to standardize, analyze, and generate insights from diagnostic and research data.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueCloud-native software for standardizing and analyzing complex healthcare data.
Specific diagnostic applications used by hospitals and laboratories for patient testing.
Data analytics and testing services used by life sciences and biopharma partners.
Customers
The company sells primarily to healthcare institutions that need software and analytics to interpret genomic and other diagnostic data in routine care. It also serves research and life sciences customers that use the platform for assay development, data analysis, and biomarker-related workflows. Customer value comes from faster interpretation, standardized analysis across sites, and the ability to expand usage across additional applications over time.
Buy oncology-focused analytics and testing applications to support cancer diagnosis and treatment decisions.
Use the platform to analyze patient samples and standardize diagnostic workflows across sites.
Purchase data analytics and research applications for biomarker and assay workflows.
Adopt modular applications to expand test menus and improve throughput and interpretation.
Strategy
The company’s strategy centers on expanding usage within existing customers and adding new clinical applications to the SOPHiA DDM platform. It is also building a broader installed base in large healthcare institutions and expanding its reach in the U.S. and other international markets, which supports a land-and-expand model.
Usage growth across customers increases platform stickiness and raises account value without relying only on new logos.
A wider menu of clinical and research applications improves relevance across more disease areas and testing workflows.
The U.S. offers a large addressable market of reference centers and hospitals that can accelerate platform adoption.
Geography
The company is headquartered in Rolle, Switzerland, and operates through subsidiaries in the U.S., France, the U.K., Brazil, Australia, Italy, and Germany. Its commercial footprint is international, with the U.S. highlighted as a major market and a key driver of customer expansion and platform adoption.
Risks
The business depends on continued adoption by hospitals, laboratories, and research customers, so sales cycles, customer concentration, and renewal/expansion risk can affect growth. Because the company is tied to healthcare data analytics, it also faces regulatory, reimbursement, clinical validation, and competition risks, along with execution risk in scaling new applications and geographies.
- Dependence on account expansionImpact: HighLikelihood: High
The platform model relies on customers adding applications over time; slower expansion would reduce growth and retention economics.
Exposure: Hospital and lab accounts
- Healthcare regulation and validationImpact: HighLikelihood: Medium
Diagnostic software and clinical applications must meet regulatory, quality, and evidence requirements in each market.
Exposure: Clinical diagnostics and research use
- Competitive pressureImpact: MediumLikelihood: High
The company competes with other clinical data analytics, sequencing, and diagnostics vendors for institutional workflows.
Exposure: Platform adoption and renewals
- Customer concentration in key centersImpact: MediumLikelihood: Medium
Large flagship customers can influence revenue momentum and reference value, creating concentration risk.
Exposure: Top cancer centers and large hospitals
Accounting
Judgemental itemsContracts may bundle platform access and services, requiring judgment on timing and performance obligations.
Impact: Can shift revenue between periods
Software and product development expenses may be capitalized when criteria are met, affecting EBITDA and intangibles.
Impact: Affects operating expense and asset balances
Equity awards are material for a technology company and require valuation assumptions.
Impact: Impacts operating costs and dilution
Actuarial assumptions and discount rates influence pension liabilities and remeasurement gains or losses.
Impact: Affects OCI and balance sheet liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Bionano Genomics, Inc.
BNGO · Laboratory Analytical Instruments
GeneDx Holdings Corp.
WGS · Services-Health Services
CS Diagnostics Corp.
CSDX · Specialty Cleaning, Polishing and Sanitation Preparations
IQVIA Holdings, Inc
IQV · Services-Commercial Physical & Biological Research
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
Last updated: 28/09/2026